Trials / Completed
CompletedNCT01723969
Screening Platform for Clinical Trials in Advanced Colorectal Cancer
Screening Platform of the EORTC for Clinical Trials in Advanced Colorectal Cancer "SPECTAcolor"
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 668 (actual)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The EORTC GastroIntestinal Tract Cancer Group and the EORTC HeadQuarters wish to set up a European screening platform for advanced colo-rectal cancer (CRC) patients. The goal of this screening platform is to provide quick access to new drugs to patients by offering a new structure for clinical trials. Currently some of the most challenging clinical questions arise from the molecular sub-division of CRC that would theoretically allow to inhibit the specific, altered pathways in the patients. A major problem for trials in this "personalized medicine" is that the low frequency of the different mutations requires a high effort for screening and identifying the patients. The EORTC CRC screening platform will hopefully offer a feasible and efficient way to characterize the patients on the molecular basis of their tumors and allow to offer them rapid and preferential participation in clinical studies with new drugs targeted to their specific pathway alterations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | Tumour markers testing | Tumour markers testing in patients advanced or metastatic colo-rectal cancer. |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2019-04-10
- Completion
- 2020-03-10
- First posted
- 2012-11-08
- Last updated
- 2022-07-07
Locations
27 sites across 11 countries: Belgium, Cyprus, France, Germany, Greece, Italy, Poland, Portugal, Spain, Sweden, Switzerland
Source: ClinicalTrials.gov record NCT01723969. Inclusion in this directory is not an endorsement.